论文部分内容阅读
目的探讨小剂量奥氮平联合帕罗西汀治疗脑卒中后抑郁的临床疗效。方法选取厦门市精神卫生中心2015年1月—2016年1月收治的脑卒中后抑郁患者80例,随机分为对照组和观察组,各40例。患者入院后均给予常规治疗,对照组患者给予帕罗西汀治疗,观察组患者在对照组基础上给予小剂量奥氮平治疗,两者患者均持续治疗8周。比较两组患者的临床疗效,治疗前及治疗后4、8周汉密顿抑郁量表(HAMD)评分、不良反应量表(TESS)评分。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者HAMD评分、TESS评分比较,差异无统计学意义(P>0.05);治疗后4、8周,观察组患者HAMD评分低于对照组(P<0.05),两组患者TESS评分比较,差异无统计学意义(P>0.05)。结论小剂量奥氮平联合帕罗斯汀治疗脑卒中后抑郁临床疗效确切,可有效缓解患者抑郁症状,且安全性高。
Objective To investigate the clinical efficacy of low-dose olanzapine combined with paroxetine in the treatment of post-stroke depression. Methods Eighty patients with post-stroke depression who were admitted to Xiamen Mental Health Center from January 2015 to January 2016 were randomly divided into control group and observation group, 40 cases in each group. All patients were given routine treatment after admission. Patients in the control group were treated with paroxetine. Patients in the observation group were given olanzapine at a low dose on the basis of the control group, and both patients were treated for 8 weeks. The clinical efficacy, HAMD score and TESS score at 4 and 8 weeks after treatment were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). Before treatment, there was no significant difference in HAMD score and TESS score between the two groups (P> 0.05). At 4 and 8 weeks after treatment, the HAMD score of the observation group was lower than that of the control group (P <0.05) There was no significant difference between the scores (P> 0.05). Conclusion Low-dose olanzapine combined with palostatin is effective in treating post-stroke depression, which can effectively alleviate the depressive symptoms of patients and is safe.